NO975218D0 - Behandling av inflammatorisk tarmsykdom ved bruk av orale doseringsformer av omega-3-polyumettede syrer - Google Patents

Behandling av inflammatorisk tarmsykdom ved bruk av orale doseringsformer av omega-3-polyumettede syrer

Info

Publication number
NO975218D0
NO975218D0 NO975218A NO975218A NO975218D0 NO 975218 D0 NO975218 D0 NO 975218D0 NO 975218 A NO975218 A NO 975218A NO 975218 A NO975218 A NO 975218A NO 975218 D0 NO975218 D0 NO 975218D0
Authority
NO
Norway
Prior art keywords
oral dosage
omega
inflammatory bowel
bowel disease
treatment
Prior art date
Application number
NO975218A
Other languages
English (en)
Other versions
NO320780B1 (no
NO975218L (no
Inventor
Thomas Buser
Emilio Paolo Camporesi
Original Assignee
Tillotts Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag
Publication of NO975218D0 publication Critical patent/NO975218D0/no
Publication of NO975218L publication Critical patent/NO975218L/no
Publication of NO320780B1 publication Critical patent/NO320780B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
NO19975218A 1995-05-15 1997-11-13 Oral doseringsform og anvendelse av omega-3-polyumettede syrer og et beleggingsmateriale for fremstilling av doseringsformen for behandling av inflammatorisk tarmsykdom. NO320780B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9509764.8A GB9509764D0 (en) 1995-05-15 1995-05-15 Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
PCT/EP1996/002038 WO1996036329A1 (en) 1995-05-15 1996-05-13 Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids

Publications (3)

Publication Number Publication Date
NO975218D0 true NO975218D0 (no) 1997-11-13
NO975218L NO975218L (no) 1997-11-13
NO320780B1 NO320780B1 (no) 2006-01-30

Family

ID=10774461

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19975218A NO320780B1 (no) 1995-05-15 1997-11-13 Oral doseringsform og anvendelse av omega-3-polyumettede syrer og et beleggingsmateriale for fremstilling av doseringsformen for behandling av inflammatorisk tarmsykdom.

Country Status (23)

Country Link
US (2) US5792795A (no)
EP (1) EP0825858B1 (no)
JP (1) JPH11509523A (no)
KR (1) KR100427112B1 (no)
CN (1) CN1104237C (no)
AT (1) ATE294575T1 (no)
AU (1) AU702692B2 (no)
BR (1) BR9608785A (no)
CA (1) CA2221356C (no)
CZ (1) CZ288560B6 (no)
DE (1) DE69634693T2 (no)
DK (1) DK0825858T3 (no)
ES (1) ES2240995T3 (no)
GB (1) GB9509764D0 (no)
HU (1) HU227282B1 (no)
IL (1) IL118240A (no)
NO (1) NO320780B1 (no)
PL (1) PL184085B1 (no)
PT (1) PT825858E (no)
SK (1) SK282062B6 (no)
TW (1) TW397683B (no)
WO (1) WO1996036329A1 (no)
ZA (1) ZA963854B (no)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6166024A (en) 1995-03-30 2000-12-26 Mayo Foundation For Medical Education And Research Use of topical azathioprine and thioguanine to treat colorectal adenomas
GB9509764D0 (en) * 1995-05-15 1995-07-05 Tillotts Pharma Ag Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
US6531150B1 (en) * 1997-10-30 2003-03-11 Morishita Jintan Co., Ltd. Encapsulated unsaturated fatty acid substance and method for producing the same
AU762246B2 (en) * 1998-02-11 2003-06-19 Rtp Pharma Corporation Method and composition for treatment of inflammatory conditions
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
DE19930030B4 (de) * 1999-06-30 2004-02-19 Meduna Arzneimittel Gmbh CO-3-ungesättigte Fettsäuren enthaltende orale Darreichungsform
US6358939B1 (en) 1999-12-21 2002-03-19 Northern Lights Pharmaceuticals, Llc Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease
US6989377B2 (en) 1999-12-21 2006-01-24 Wisconsin Alumni Research Foundation Treating vitamin D responsive diseases
EP1339392A2 (en) * 2000-12-06 2003-09-03 S.L.A. Pharma AG Solid polyunsaturated fatty acid compositions
US6548646B1 (en) * 2001-08-23 2003-04-15 Bio-Rad Laboratories, Inc. Reference control for high-sensitivity C-reactive protein testing
US20030144219A1 (en) * 2001-11-15 2003-07-31 Phinney Stephen Dodge Formulations and methods for treatment or amelioration of inflammatory conditions
US20030118329A1 (en) * 2001-12-21 2003-06-26 Pere Obrador Video indexing using high resolution still images
EP2295529B2 (en) * 2002-07-11 2022-05-18 Basf As Use of a volatile environmental pollutants-decreasing working fluid for decreasing the amount of pollutants in a fat for alimentary or cosmetic use
SE0202188D0 (sv) * 2002-07-11 2002-07-11 Pronova Biocare As A process for decreasing environmental pollutants in an oil or a fat, a volatile fat or oil environmental pollutants decreasing working fluid, a health supplement, and an animal feed product
AU2002951913A0 (en) * 2002-10-08 2002-10-24 Chevis Agriservices & Consulting Pty. Limited Method of treatment
US20050152969A1 (en) * 2004-01-08 2005-07-14 Chiprich Timothy B. Colored liquid-filled soft capsules and method of manufacture thereof
BRPI0506771A (pt) 2004-01-12 2007-05-22 Applied Molecular Evolution anticorpo, e, composição farmacêutica
EP1722630A4 (en) * 2004-01-20 2009-05-27 Richard F Harty COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISEASES
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
GB0413729D0 (en) * 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
GB0413730D0 (en) * 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
US8758814B2 (en) 2004-10-08 2014-06-24 Mcneil-Ppc, Inc. Chewable enteric coated aspirin tablets
US20090011012A1 (en) * 2007-07-06 2009-01-08 Baum Seth J Fatty acid compositions and methods of use
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
EP3578177A1 (en) 2008-09-02 2019-12-11 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
US20100130608A1 (en) * 2008-10-01 2010-05-27 Martek Biosciences Corporation Compositions and methods for reducing triglyceride levels
WO2010042933A2 (en) 2008-10-10 2010-04-15 Northwestern University Inhibition and treatment of prostate cancer metastasis
AU2010222648B2 (en) 2009-03-09 2016-07-07 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
US9901551B2 (en) * 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
EP2424521A4 (en) 2009-04-29 2015-03-04 Amarin Pharmaceuticals Ie Ltd PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND CARDIOVASCULAR AGENT AND METHODS OF USE
PL2424356T3 (pl) 2009-04-29 2018-03-30 Amarin Pharmaceuticals Ireland Limited Stabilna farmaceutyczna kompozycja i sposoby jej stosowania
CA3026006C (en) 2009-06-15 2021-09-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
MX2012003555A (es) 2009-09-23 2012-07-03 Amarin Corp Plc Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma.
ES2895477T3 (es) * 2009-10-23 2022-02-21 Basf As Cápsulas y comprimidos revestidos de una mezcla de aceites de ácidos grasos
CN104220875A (zh) 2010-10-19 2014-12-17 埃尔舍利克斯治疗公司 基于化学感应受体配体的治疗
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
EP2646013A4 (en) 2010-11-29 2014-03-26 Amarin Pharma Inc COMPOSITION WITH LOW IMPACT EFFECT AND METHOD FOR THE TREATMENT AND / OR PREVENTION OF CARDIOVASCULAR DISEASES IN A PATIENT WITH FISH ALLERGY / SENSITIVITY
KR101310710B1 (ko) * 2011-03-23 2013-09-27 한미약품 주식회사 오메가-3 지방산 에스테르 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 경구용 복합 조성물
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US8551551B2 (en) 2012-01-06 2013-10-08 Perlman Consulting, Llc Stabilization of omega-3 fatty acids in saturated fat microparticles having low linoleic acid content
WO2013103902A1 (en) 2012-01-06 2013-07-11 Omthera Pharmaceuticals, Inc. Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
EP2800469B1 (en) 2012-01-06 2021-08-25 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
TW201347754A (zh) 2012-05-07 2013-12-01 Omthera Pharmaceuticals Inc 史他汀及ω－３脂肪酸之組合物
MX2020013922A (es) 2012-06-29 2022-08-15 Amarin Pharmaceuticals Ie Ltd Metodos para reducir riesgo de evento cardiovascular en sujeto con terapia con estatina.
GB201216385D0 (en) 2012-09-13 2012-10-31 Chrysalis Pharma Ag A pharmaceutical composition
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
EP2745709A1 (en) * 2012-12-24 2014-06-25 Abbott Laboratories, Inc. Nutritional compositions with reduced beta-casein a1 and related methods
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US9839625B2 (en) 2014-11-06 2017-12-12 Northwestern University Inhibition of cancer cell motility
MA41611A (fr) 2015-02-23 2018-01-02 Omthera Pharmaceuticals Inc Préparations en milli-capsules comprenant des acides gras polyinsaturés libres
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
FR3061151B1 (fr) * 2016-12-26 2019-05-24 Belles Feuilles Procede et systeme pour conditionner un compose lipidique en doses, capsules de compose lipidique ainsi obtenues et applications de ces capsules.
FR3061019B1 (fr) * 2016-12-26 2019-05-24 Belles Feuilles Procede et systeme pour conditionner des composes lipidiques pour alicaments ou medicaments.
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
MA51766A (fr) 2018-09-24 2020-12-16 Amarin Pharmaceuticals Ie Ltd Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
KR200490037Y1 (ko) 2019-04-17 2019-09-11 트랜드 주식회사 원터치 작동방식 욕실 청소용 물분사 헤드
EP3972430A1 (en) * 2019-05-23 2022-03-30 Evonik Operations GmbH Preparation for use in enhancing formation of short-chain fatty acids (scfas)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8505569D0 (sv) * 1985-11-25 1985-11-25 Aco Laekemedel Ab Enteralt preparat
US5252333A (en) * 1987-04-27 1993-10-12 Scotia Holdings Plc Lithium salt-containing pharmaceutical compositions
ES2040847T3 (es) * 1987-04-27 1996-07-16 Efamol Holdings Un procedimiento para preparar una composicion farmaceutica que contiene una sal de litio.
GB2223943A (en) * 1988-10-21 1990-04-25 Tillotts Pharma Ag Oral disage forms of omega-3 polyunsaturated acids
WO1994012159A1 (en) * 1992-11-30 1994-06-09 Pfizer Inc. Supported liquid membrane delivery devices
US5411988A (en) * 1993-10-27 1995-05-02 Bockow; Barry I. Compositions and methods for inhibiting inflammation and adhesion formation
GB9509764D0 (en) * 1995-05-15 1995-07-05 Tillotts Pharma Ag Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids

Also Published As

Publication number Publication date
AU702692B2 (en) 1999-03-04
ES2240995T3 (es) 2005-10-16
CN1104237C (zh) 2003-04-02
SK152397A3 (en) 1998-05-06
CZ288560B6 (cs) 2001-07-11
AU5895596A (en) 1996-11-29
DE69634693D1 (de) 2005-06-09
CA2221356A1 (en) 1996-11-21
EP0825858A1 (en) 1998-03-04
CZ360797A3 (cs) 1998-06-17
US5792795A (en) 1998-08-11
GB9509764D0 (en) 1995-07-05
DE69634693T2 (de) 2006-05-04
NO320780B1 (no) 2006-01-30
HU227282B1 (en) 2011-01-28
WO1996036329A1 (en) 1996-11-21
MX9708758A (es) 1998-03-31
KR19990014767A (ko) 1999-02-25
CN1184421A (zh) 1998-06-10
TW397683B (en) 2000-07-11
US5948818A (en) 1999-09-07
IL118240A (en) 2001-01-28
ATE294575T1 (de) 2005-05-15
SK282062B6 (sk) 2001-10-08
PL184085B1 (pl) 2002-08-30
PL323362A1 (en) 1998-03-30
EP0825858B1 (en) 2005-05-04
IL118240A0 (en) 1996-09-12
PT825858E (pt) 2005-08-31
CA2221356C (en) 2003-12-30
KR100427112B1 (ko) 2004-09-16
HUP9900337A2 (hu) 1999-06-28
HUP9900337A3 (en) 2001-12-28
DK0825858T3 (da) 2005-08-15
ZA963854B (en) 1997-11-17
JPH11509523A (ja) 1999-08-24
NO975218L (no) 1997-11-13
BR9608785A (pt) 1999-07-06

Similar Documents

Publication Publication Date Title
NO975218D0 (no) Behandling av inflammatorisk tarmsykdom ved bruk av orale doseringsformer av omega-3-polyumettede syrer
ATE202473T1 (de) Rasch freisetzende tablettenkerne mit unlöslichen arzneistoffen und mit einem retardüberzug
CA2065809A1 (en) Gastroresistant pharmaceutical formulations for oral administration containing salts of bile acids
ATE129893T1 (de) Orale dosierungsform mit verzögerter wirkstoffabgabe für die behandlung von intestinalen krankheiten.
KR920000324A (ko) 필수 지방산 처리법
ATE30380T1 (de) Pharmazeutische formulierungen mit mehrfachen einheiten.
PL327323A1 (en) Orally administered 5-asa containing pharmaceutic composition of modified active substance release and method of treating intestinal diseases

Legal Events

Date Code Title Description
MK1K Patent expired